| ［1］ Ochiumi T, Tanaka S, Oka S, et al. Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma［J］. Int J Oncol,2004,24(3):539-547.［2］ 吴丽, 王凯, 吴小丽,等. 卵巢上皮性癌中表达Tie2单核巨噬细胞的研究［J］. 中国实用妇科与产科杂志,2013,29(8):657-661.［3］ 吴丽, 汪希鹏. 表达Tie2单核巨噬细胞在肿瘤进展中的作用［J］. 中国免疫学杂志, 2013,29(4):426-429.［4］ Ai Z, Yin L, Zhou X, et al. Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer［J］. Cancer,2006,107(4):746-756.［5］ Imanishi Y, Hu B, Jarzynka MJ, et al. Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway［J］. Cancer Res,2007,67(9):4254-4263.［6］ Dumont DJ, Anderson L, Breitman ML, et al. Assignment of the endothelial-specific protein receptor tyrosine kinase gene (TEK) to human chromosome 9p21［J］. Genomics,1994,23(2):512-513.［7］ Fiedler U, Krissl T, Koidl S, et al. Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats［J］. J Biol Chem,2003,278(3):1721-1727.［8］ Kioi M, Vogel H, Schultz G, et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice［J］. J Clin Invest,2010,120(3):694-705.［9］ Du R, Lu KV, Petritsch C, et al. HIF1 alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion［J］. Cancer Cell,2008,13(3):206-220.［10］ Pucci F, Venneri MA, Biziato D, et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships［J］. Blood,2009,114(4):901-914.［11］ Squadrito ML, De Palma M. Macrophage regulation of tumor angiogenesis: implications for cancer therapy［J］. Mol Aspects Med,2011,32(2):123-145.［12］ Coffelt SB, Chen YY, Muthana M, et al. Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion［J］. J Immunol,2011,186(7):4183-4190.［13］ Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease［J］. Aliment Pharmacol Ther,2003,18Suppl2:1-5.［14］ De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors［J］. Cancer Cell,2005,8(3):211-226.［15］ Pucci F, Venneri MA, Biziato D, et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships［J］. Blood,2009,114(4):901-914.［16］ Murdoch C, Tazzyman S, Webster S, et al. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2［J］. J Immunol,2007,178(11):7405-7411.［17］ Mazzieri R, Pucci F, Moi D, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells［J］. Cancer Cell,2011,19(4):512-526.［18］ Murdoch C, Tazzyman S, Webster S, et al. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2［J］. J Immunol,2007,178(11):7405-7411.［19］ Schulz P, Fischer C, Detjen KM, et al. Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer［J］. Faseb J,2011,25(10):3325-3335.［20］ Albini A, Noonan DM. Angiopoietin2 and Tie2: tied to lymphangiogenesis and lung metastasis:new perspectives in antimetastatic antiangiogenic therapy［J］. J Natl Cancer Inst,2012,104(6):429-431. （2014-03-22收稿 2014-06-25修回） |
